GlassScriptPhysician profile
Michel A Bibawy
NPI 1922107804
$1,260.43
in general payments reported to CMS, 2019-2025
21 companies · $237 in 2025
The $237 reported for 2025 was more than what 83% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.94 · 2020: $93.46 · 2021: $75.76 · 2022: $163 · 2023: $194 · 2024: $478 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $910.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $909.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $214.04 | 2022-2024 | Mounjaro, Trulicity, Jardiance |
| Penumbra, INC. | $149.41 | 2024 | Penumbra System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $100.09 | 2019-2025 | Xifaxan |
| Medtronic Vascular, INC. | $80.57 | 2020 | |
| Ardelyx, INC. | $75.61 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $72.28 | 2021-2023 | Ocaliva |
| Merck Sharp & Dohme LLC | $65.78 | 2024 | Dificid |
| Ironwood Pharmaceuticals, INC | $65.28 | 2024 | |
| Phathom Pharmaceuticals, INC. | $56.27 | 2024-2025 | Voquezna |
| Abbvie INC. | $53.70 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.16 | 2025 | Entyvio |
| Blueprint Medicines Corporation | $47.15 | 2023-2025 | Ayvakit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $46.32 | 2023-2024 | Jardiance |
| Braintree Laboratories, INC. | $45.96 | 2023-2025 | Sutab, Suflave |
| Bayer Healthcare Pharmaceuticals INC. | $24.92 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $23.34 | 2024 | |
| Currax Pharmaceuticals LLC | $22.38 | 2021 | |
| Xeris Pharmaceuticals, INC. | $19.81 | 2022 | |
| Esperion Therapeutics, INC. | $18.38 | 2024 | Nexletol |
| Teva Pharmaceuticals USA, INC. | $16.16 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Bibawy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.